FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average I	ourden									
hours nor resnance	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 Name and Address of Departing Devoca*				2	2. Issuer Name <b>and</b> Ticker or Trading Symbol									5. Relationship of Reporting Person(s) to Issuer						
1. Name and Address of Reporting Person						Deciphera Pharmaceuticals, Inc. [ DCPH ]									(Check all applicable)					
Kelly Thomas Patrick						becapita i marmaceaticato, inc. [ Doi ii ]									Director		10% Owner		·	
					-									X	Officer (give title below)			Other (s	specify	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)									,		acial	,		
C/O DECIPHERA PHARMACEUTICALS, INC.						08/13/2019								Chief Financial Officer						
500 TOT	TEN PONI																			
			_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable							
(Street)																Line)				
WALTH.	AM M	ΙA	02451												X Form filed by One Reporting Person					
															Form filed by More than One Reporting Person					
(City) (State) (Zip)														1 615611						
(=.5)			(																	
		Tab	le I - I	Non-Deri	ivativ	e Sec	curit	ies Ad	quire	ed, D	isposed o	f, or B	enefi	cially	Owned					
1. Title of	Security (Inst	tr. 3)		2. Transac	tion				3.		4. Securities				5. Amount of				7. Nature	
				Date (Month/Da	v/Year)	Exec	ecution Date, nv		Transaction Code (Instr.		Disposed Of (D) (Instr. 3, 4 and			d 5)	Securition Benefici			Form: Direct (D) or Indirect	of Indirect Beneficial	
				`		(Month/Day/Year)		y/Year)	8)							d Following			Ownership (Instr. 4)	
										l <sub>v</sub>	Amount	(A) or (D)	Price		Transac	tion(s)			(1130.4)	
					Code			(D)			(Instr. 3	and 4)								
Common Stock 08/1					2019	)19					11,250	A	\$1	1.89		1,250		D		
Common Stock 08/13/20					2019	19			<b>S</b> <sup>(1)</sup>		7,264 D \$40.68		5894 <sup>(2)</sup>	4 <sup>(2)</sup> 3,986		D				
Common Stock 08/13/201					2019	19			S <sup>(1)</sup>		3,586	D	\$42.2	2.2534 <sup>(3)</sup>		400		D		
								-(1)	Н											
Common Stock 08/13/201				2019	19		S <sup>(1)</sup>		400	D	\$42.9	9175(4)	0			D				
		-	Table	I - Deriv	ative	Secu	ıritie	s Acc	uirec	d, Dis	posed of,	or Bei	nefici	ally O	wned					
(e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of	2.	3. Transaction	3A. De		4.		5. N	umber			cisable and	7. Title a			Price of	9. Number		10.	11. Nature	
Derivative Security	Conversion or Exercise	Date (Month/Day/Year)	if any	ion Date,	Transa Code (I		of Derivative Securities		Expiration D (Month/Day/			of Securities Underlying			Derivative Security	derivative Securities		Ownership Form:	of Indirect Beneficial	
(Instr. 3)	Price of			/Day/Year)	8)				(	ши	i cui j	Derivative Secu			nstr. 5)	Beneficially		Direct (D)	Ownership	
	Derivative						Acquired (A) or					(Instr. 3	and 4)			Owned Following		or Indirect (I) (Instr. 4)	(Instr. 4)	
	,						Disp	osed O) (Instr.								Reported Transaction	nn(e)	,		
							3, 4 and 5)									(Instr. 4)	(5)			
														ount						
													or Nun	nber						
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	of Sha	res						
Stock							H	· ,					+						<del>                                     </del>	
Option	\$1.89	08/13/2019			M			11,250	(	(5)	12/17/2025	Commo	n   11	250	\$0.00	138,00	8	D		
(Right to Buy)	1							,50	`			Stock	11,					_		

## **Explanation of Responses:**

- $1. \ The sales \ reported in this \ Form \ 4 \ were \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ the \ reporting \ person.$
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$40.11 to \$41.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$41.71 to \$42.61, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.90 to \$42.97, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 5. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates.

## Remarks:

/s/ Thomas P. Kelly

08/13/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\*\* Signature of Reporting Person Date

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.